RU97105384A - APPLICATION OF 5-HT1F AGONISTS FOR INHIBITION OF 5HT1F- MEDIATED NEUROGENIC MINGIAL TRANSUSIONS - Google Patents

APPLICATION OF 5-HT1F AGONISTS FOR INHIBITION OF 5HT1F- MEDIATED NEUROGENIC MINGIAL TRANSUSIONS

Info

Publication number
RU97105384A
RU97105384A RU97105384/14A RU97105384A RU97105384A RU 97105384 A RU97105384 A RU 97105384A RU 97105384/14 A RU97105384/14 A RU 97105384/14A RU 97105384 A RU97105384 A RU 97105384A RU 97105384 A RU97105384 A RU 97105384A
Authority
RU
Russia
Prior art keywords
agonist
transusions
mingial
5ht1f
inhibition
Prior art date
Application number
RU97105384/14A
Other languages
Russian (ru)
Other versions
RU2183457C2 (en
Inventor
Эдмунд Аудиа Джеймс
Энн Бранчек Тереза
Лоис Кохен Марлен
Вилис Джонсон Кирк
Алан Фебас Ли
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/318,330 external-priority patent/US5698571A/en
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of RU97105384A publication Critical patent/RU97105384A/en
Application granted granted Critical
Publication of RU2183457C2 publication Critical patent/RU2183457C2/en

Links

Claims (7)

1. Применение 5-HT1F агониста, который проявляет минимальные сосудосуживающие свойства, для производства лекарственного средства для предупреждения или лечения мигреневой боли.1. The use of a 5-HT 1F agonist, which exhibits minimal vasoconstrictive properties, for the manufacture of a medicament for the prevention or treatment of migraine pain. 2. Применение 5-HT1F агониста, который проявляет минимальные сосудосуживающие свойства, для производства лекарственного средства для ингибирования нейрогенной менингиальной транссудации.2. The use of a 5-HT 1F agonist, which exhibits minimal vasoconstrictive properties, for the manufacture of a medicament for inhibiting neurogenic meningeal extravasation. 3. Применение 5-HT1F агониста по любому из п.п. 1 или 2, где указанный 5-HT1F агонист обладает Индексом Специфичности в интервале 5-10000.3. The use of a 5-HT 1F agonist according to any one of paragraphs. 1 or 2, wherein said 5-HT 1F agonist has a Specificity Index in the range of 5-10000. 4. Применение 5-HT1F по любому из п.п. 1 или 2, где указанный 5-HT1F агонист обладает Индексом Специфичности по меньшей мере 10.4. The use of 5-HT 1F according to any one of paragraphs. 1 or 2, wherein said 5-HT 1F agonist has a Specificity Index of at least 10. 5. Применение 5-HT1F по любому из п.п. 1 или 2, где указанный 5-HT1F агонист обладает Индексом Специфичности по меньшей мере 100.5. The use of 5-HT 1F according to any one of paragraphs. 1 or 2, wherein said 5-HT 1F agonist has a Specificity Index of at least 100. 6. Применение 5-HT1F по любому из п.п. 1 или 2, где указанный 5-HT1F агонист обладает Индексом Специфичности по меньшей мере 1000.6. The use of 5-HT 1F according to any one of paragraphs. 1 or 2, wherein said 5-HT 1F agonist has a Specificity Index of at least 1000. 7. Применение 5-HT1F агониста по любому из п.п. 1 или 2, где указанный 5-HT1F агонист обладает Индексом Специфичности по меньшей мере 10000.7. The use of a 5-HT 1F agonist according to any one of paragraphs. 1 or 2, wherein said 5-HT 1F agonist has a Specificity Index of at least 10,000.
RU97105384/14A 1994-10-05 1995-10-03 Method for applying 5_ht5-ht1f-antagonist for inhibiting 5_ht5-ht1f-mediated neurogenic meningeal transudation RU2183457C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/318,330 1994-10-05
US08/318,330 US5698571A (en) 1994-10-05 1994-10-05 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine

Publications (2)

Publication Number Publication Date
RU97105384A true RU97105384A (en) 1999-05-20
RU2183457C2 RU2183457C2 (en) 2002-06-20

Family

ID=23237717

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97105384/14A RU2183457C2 (en) 1994-10-05 1995-10-03 Method for applying 5_ht5-ht1f-antagonist for inhibiting 5_ht5-ht1f-mediated neurogenic meningeal transudation

Country Status (14)

Country Link
US (1) US5698571A (en)
EP (1) EP0705600A1 (en)
JP (1) JPH08208516A (en)
AU (1) AU688168B2 (en)
CA (1) CA2159767A1 (en)
CZ (1) CZ93097A3 (en)
HU (1) HUT77885A (en)
NO (1) NO971487D0 (en)
NZ (1) NZ296252A (en)
RU (1) RU2183457C2 (en)
TW (1) TW492864B (en)
UA (1) UA44284C2 (en)
WO (1) WO1996011006A1 (en)
ZA (1) ZA958314B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406859B1 (en) 1992-01-08 2002-06-18 Synaptic Pharmaceutical Corporation DNA encoding a 5-HT 1F receptor and uses thereof
EP0749962B1 (en) * 1995-06-23 2000-11-02 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US5962473A (en) * 1996-08-16 1999-10-05 Eli Lilly And Company Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F
CA2264267A1 (en) * 1996-08-28 1998-03-05 Michael Edward Flaugh Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2-aminocyclohepta¬b|benzofurans
AU4074897A (en) * 1996-09-18 1998-04-14 Eli Lilly And Company A method for the prevention of migraine
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
WO2000006082A2 (en) * 1998-07-27 2000-02-10 Eli Lilly And Company Treatment of anxiety disorders
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
US6255334B1 (en) * 1998-10-30 2001-07-03 Pfizer Inc 5HT 1 receptor agonists and metoclopramide for the treatment of migraine
CA2535082C (en) * 2000-11-27 2013-11-19 Terry Cassaday Chair or bed member having data storage
DE60228294D1 (en) * 2001-06-05 2008-09-25 Ronald Aung-Din Topische migränetherapie
US8329734B2 (en) * 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
ES2421511T3 (en) 2001-12-21 2013-09-03 X Ceptor Therapeutics Inc LXR modulators
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
TWI263497B (en) * 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
US7332183B2 (en) * 2002-12-26 2008-02-19 Pozen Inc. Multilayer dosage forms containing NSAIDs and triptans
CA2529528A1 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
CA2569964A1 (en) * 2004-06-10 2005-12-29 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
JP2008521771A (en) 2004-11-26 2008-06-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Isoxazoline-indole derivatives having improved antipsychotic and anxiolytic activity
WO2010005507A1 (en) 2008-06-30 2010-01-14 Afgin Pharma, Llc Topical regional neuro-affective therapy
CA2757019C (en) * 2009-04-02 2018-05-15 Colucid Pharmaceuticals, Inc. Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
WO2011123654A1 (en) 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists
CN107530318A (en) 2015-03-02 2018-01-02 阿福金制药有限责任公司 Sex therapy is influenceed with the regional area nerve of cannboid
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
TWI826514B (en) * 2018-09-04 2023-12-21 美商美國禮來大藥廠 Chronic nightly dosing of lasmiditan for migraine prevention
TWI829107B (en) 2019-07-09 2024-01-11 美商美國禮來大藥廠 Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360735A (en) * 1992-01-08 1994-11-01 Synaptic Pharmaceutical Corporation DNA encoding a human 5-HT1F receptor, vectors, and host cells

Similar Documents

Publication Publication Date Title
RU97105384A (en) APPLICATION OF 5-HT1F AGONISTS FOR INHIBITION OF 5HT1F- MEDIATED NEUROGENIC MINGIAL TRANSUSIONS
CA2119745A1 (en) Nonpeptidyl integrin inhibitors having specificity for gpiibiiia receptor
HK1033907A1 (en) Metal chelators for use in the treatment of alzheimer's disease.
ATE327743T1 (en) SERTRALINE FOR THE TREATMENT OF SOCIAL PHOBIA
ES2174465T3 (en) TRIAZOL COMPOUNDS AND ITS USE AS DOPAMINE-D.
EA200200649A1 (en) COMBINATION OF SEROTONIN RETURN CAPTURE INHIBITOR AND ANTAGONIST, REVERSE AGONIST OR REPUBLIC AGONIST 5-NT2C RECEPTOR
ES2176600T3 (en) DERIVATIVE OF PROPIOFENONE AND PROCEDURES FOR PREPARATION.
BRPI0311323B8 (en) sglt2 c-aryl glycoside inhibitor compound, pharmaceutical composition and combination
EP0826671A4 (en) Heterocyclic amide compounds and medicinal use of the same
CA2407100A1 (en) 1-aroyl-piperidinyl benzamidines
BR0009563A (en) Biphenyl ap2 inhibitors containing heterocyclic and method
BR9809968A (en) Application of thiazolidinedione derivatives in the treatment of pcos and gestational diabetes
NO990522D0 (en) Use of <beta> -sheet mimetics as protease and kinase inhibitors of transcription factors
WO2002080939A3 (en) Ionene polymers and their use as antimicrobial agents
MX9803809A (en) Biphenyl hydroxamate inhibitors of matrix metalloproteinases.
BR0113389A (en) Compounds that inhibit factor xa activity
DK0772604T3 (en) Trialzole compounds and their use as dopamine D3 ligands
KR970704438A (en) Use of Thiazole and Thiadiazole Compounds as D Dopamine Receptor Ligands
PT1056454E (en) UTILIZATION OF MACROLID COMPOUNDS FOR THE TREATMENT OF GLAUCOMA
BR0008416A (en) Pharmaceutical compound, formulation and composition, methods for inhibiting the potassium flow of a cell, for the treatment or prevention of a sickle cell disease event, and for improving the resistance to degradation in a biological medium of a potassium channel inhibitor comprising a phenyl portion
GB9716219D0 (en) Prevention of metastases
BR9901058A (en) N-cail and n-aroyl aralkyl amides.
SE9902267D0 (en) New compounds
KR950016735A (en) How to suppress Turner syndrome
EP1121932A4 (en) Remedies for ocular diseases